Literature DB >> 11160752

Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.

J A Zaia1, G Gallez-Hawkins, X Li, Z Q Yao, N Lomeli, K Molinder, C La Rosa, D J Diamond.   

Abstract

To determine if mutations of an immunodominant HLA-restricted cytomegalovirus (CMV) peptide sequence occur in nature, the sequence corresponding to the HLA A*0201-specific peptide CMVpp65(495-503) was determined in 50 human CMV isolates. Rare mutations were detected; 6 of 50 were silent mutations at the amino terminus of the peptide, while 3 of 50 were mutations of the native methionine residue to isoleucine (M499I). The observed M499I mutation in three isolates decreased cytolytic targeting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160752      PMCID: PMC114832          DOI: 10.1128/JVI.75.5.2472-2474.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.

Authors:  K C Parker; M A Bednarek; L K Hull; U Utz; B Cunningham; H J Zweerink; W E Biddison; J E Coligan
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

2.  Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.

Authors:  Z Gyulai; V Endresz; K Burian; S Pincus; J Toldy; W I Cox; C Meric; S Plotkin; E Gönczöl; K Berencsi
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals.

Authors:  A Gallina; E Percivalle; L Simoncini; M G Revello; G Gerna; G Milanesi
Journal:  J Gen Virol       Date:  1996-06       Impact factor: 3.891

4.  Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells.

Authors:  S B Boppana; W J Britt
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

5.  Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.

Authors:  G M Gallez-Hawkins; B R Tegtmeier; A ter Veer; J C Niland; S J Forman; J A Zaia
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

6.  Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.

Authors:  J A Zaia; G M Schmidt; N J Chao; N W Rizk; A P Nademanee; J C Niland; D A Horak; J Lee; G Gallez-Hawkins; C R Kusnierz-Glaz
Journal:  Biol Blood Marrow Transplant       Date:  1995-12       Impact factor: 5.742

7.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

Authors:  D J Diamond; J York; J Y Sun; C L Wright; S J Forman
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

8.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

Authors:  M R Wills; A J Carmichael; K Mynard; X Jin; M P Weekes; B Plachter; J G Sissons
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

Authors:  E McLaughlin-Taylor; H Pande; S J Forman; B Tanamachi; C R Li; J A Zaia; P D Greenberg; S R Riddell
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

10.  Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.

Authors:  A Solache; C L Morgan; A I Dodi; C Morte; I Scott; C Baboonian; B Zal; J Goldman; J E Grundy; J A Madrigal
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

View more
  7 in total

1.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

2.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

3.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

5.  T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection.

Authors:  George C Wang; Pradyot Dash; Jonathan A McCullers; Peter C Doherty; Paul G Thomas
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

6.  Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.

Authors:  Sabine Tischer; Megan Basila; Britta Maecker-Kolhoff; Stephan Immenschuh; Mathias Oelke; Rainer Blasczyk; Britta Eiz-Vesper
Journal:  J Transl Med       Date:  2011-10-12       Impact factor: 5.531

Review 7.  Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.

Authors:  Sara Scarpini; Francesca Morigi; Ludovica Betti; Arianna Dondi; Carlotta Biagi; Marcello Lanari
Journal:  Vaccines (Basel)       Date:  2021-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.